DUOX2 (Gene)

Organism:

Homo sapiens

Synonyms:DUOX2, ENTREZ:50506, HGNC:13273, LNOX2, MIM:606759, NM_001363711, NM_014080, NOXEF2, NP_001350640, NP_054799, P138-TOX, TDH6, THOX2, dual oxidase 2

Omim:OMIM:606759

Id:ENSG00000140279

Hgnc:HGNC:13273

Entrez:50506

Ensembl:ENSG00000140279

Description:dual oxidase 2

The protein encoded by this gene is a glycoprotein and a member of the NADPH oxidase family. The synthesis of thyroid hormone is catalyzed by a protein complex located at the apical membrane of thyroid follicular cells. This complex contains an iodide transporter, thyroperoxidase, and a peroxide generating system that includes this encoded protein and DUOX1. This protein is known as dual oxidase because it has both a peroxidase homology domain and a gp91phox domain. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View DUOX2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with DUOX2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using DUOX2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for DUOX2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with DUOX2.

Results found

Linked to

	Label	Description
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193351 ruxolitinib 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 10 V 5 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 5 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680,GSE182683 10 V 4 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE162276 2 V 3 ROSIGLITAZONE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE153189 1 V 3 INTERFERON GAMMA MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE228106 3 V 2 PACLITAXEL HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE92965 0 V 1 TAMOXIFEN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS

GSE239844 crizotinib 6 v 9 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE193351 ruxolitinib 1 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 10 V 5 CISPLATIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 5 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE182680,GSE182683 10 V 4 DEXAMETHASONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE97616 GSE97617 NOK overexpression HEK RNA Small Interfering 7 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE162276 2 V 3 ROSIGLITAZONE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE153189 1 V 3 INTERFERON GAMMA MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE228106 3 V 2 PACLITAXEL HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE92965 0 V 1 TAMOXIFEN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.